Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study

Blood Cancer J. 2016 Nov 18;6(11):e501. doi: 10.1038/bcj.2016.113.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Blood Proteins / analysis
  • Blood Proteins / immunology
  • Cyclophosphamide / therapeutic use
  • Cytarabine / administration & dosage
  • Doxorubicin / therapeutic use
  • Etoposide / therapeutic use
  • Female
  • Humans
  • Immunophenotyping / methods*
  • Lymphoma, Follicular / blood
  • Lymphoma, Follicular / diagnosis
  • Lymphoma, Follicular / drug therapy
  • Lymphoma, Follicular / immunology
  • Lymphoma, Large B-Cell, Diffuse / blood*
  • Lymphoma, Large B-Cell, Diffuse / diagnosis
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large B-Cell, Diffuse / mortality
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Monitoring, Physiologic / methods
  • Prednisolone / therapeutic use
  • Prednisone / therapeutic use
  • Prognosis
  • Protein Array Analysis / methods*
  • Proteomics / methods
  • Risk Factors
  • Rituximab
  • Survival Analysis
  • Vincristine / therapeutic use
  • Young Adult

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Blood Proteins
  • R-CHOP protocol
  • Cytarabine
  • Rituximab
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone
  • Prednisone
  • Methotrexate

Supplementary concepts

  • CHOEP protocol